Volume 11, Issue 4 (2025)
Pharm Biomed Res 2025, 11(4): 331-338 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Salehifar E, Bagherzadegan Z, Ala S, Ramezaninejad S. Albumin Utilization Evaluation in a Teaching University Hospital in Iran. Pharm Biomed Res 2025; 11 (4) :331-338
URL: http://pbr.mazums.ac.ir/article-1-711-en.html
URL: http://pbr.mazums.ac.ir/article-1-711-en.html
1- Department of Clinical Pharmacy, Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Institute of Herbal Medicines and Metabolic Disorders, Mazandaran University of Medical Sciences, Sari, Iran.
2- Department of Pharmaceutical Care, Emam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran.
3- Department of Clinical Pharmacy, School of Pharmacy, Babol University of Medical Sciences, Babol, Iran.
2- Department of Pharmaceutical Care, Emam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran.
3- Department of Clinical Pharmacy, School of Pharmacy, Babol University of Medical Sciences, Babol, Iran.
Abstract: (48 Views)
Background: Human albumin solution (HAS) is an expensive colloidal preparation that is commonly used in clinical practice. Given the high cost of albumin and its rising worldwide use, it is imperative to establish a practical protocol to improve the rational use of albumin products. This study aimed to identify albumin utilization patterns in a teaching hospital and to demonstrate the importance of revisiting strategies for albumin administration.
Objectives: This study aimed to identify albumin utilization patterns in a teaching hospital and to demonstrate the importance of revisiting strategies for albumin administration.
Methods: This retrospective study was conducted between March 20, 2023, and March 19, 2024, at Imam Khomeini Educational Hospital, an affiliated hospital of Mazandaran University of Medical Sciences, Sari City, Iran. All albumin forms completed during the study period were enrolled for appropriateness evaluation in accordance with the protocol developed by the Iranian Food and Drug Administration.
Results: In 82 patients (32.1%), serum albumin levels were greater than 2.5 g/dL at the time of albumin administration, of which 56% were above the recommended cut-off for the indication. Among 313 albumin prescriptions, in 7 cases (2.3%), albumin administration was not based on any official indication listed in the protocol. Albumin level less than 2.5 g/dL for 3 days (25.4%), ascites or generalized edema (24.4%), and hepatorenal syndrome (HRS) (13%) were the most common reasons for albumin administration. The daily albumin dose ranged from 1 vial of 20% to 5 vials, averaging 19 g/d. Only one patient (0.3%) had the duration of albumin treatment stated, and no patient had their albumin levels rechecked 72 hours after administration.
Conclusion: This study showed significant deviations from the albumin prescription protocol. Some aspects of albumin prescribing, including the minimum cut-off for starting albumin, the duration of use, and rechecking the albumin level, were not adequately considered by physicians. These findings highlight a more sophisticated focus on albumin prescribing in an attempt to minimize the irrational prescription of this expensive and valuable drug.
Objectives: This study aimed to identify albumin utilization patterns in a teaching hospital and to demonstrate the importance of revisiting strategies for albumin administration.
Methods: This retrospective study was conducted between March 20, 2023, and March 19, 2024, at Imam Khomeini Educational Hospital, an affiliated hospital of Mazandaran University of Medical Sciences, Sari City, Iran. All albumin forms completed during the study period were enrolled for appropriateness evaluation in accordance with the protocol developed by the Iranian Food and Drug Administration.
Results: In 82 patients (32.1%), serum albumin levels were greater than 2.5 g/dL at the time of albumin administration, of which 56% were above the recommended cut-off for the indication. Among 313 albumin prescriptions, in 7 cases (2.3%), albumin administration was not based on any official indication listed in the protocol. Albumin level less than 2.5 g/dL for 3 days (25.4%), ascites or generalized edema (24.4%), and hepatorenal syndrome (HRS) (13%) were the most common reasons for albumin administration. The daily albumin dose ranged from 1 vial of 20% to 5 vials, averaging 19 g/d. Only one patient (0.3%) had the duration of albumin treatment stated, and no patient had their albumin levels rechecked 72 hours after administration.
Conclusion: This study showed significant deviations from the albumin prescription protocol. Some aspects of albumin prescribing, including the minimum cut-off for starting albumin, the duration of use, and rechecking the albumin level, were not adequately considered by physicians. These findings highlight a more sophisticated focus on albumin prescribing in an attempt to minimize the irrational prescription of this expensive and valuable drug.
Type of Study: Original Research |
Subject:
Clinical Pharmacy
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
